Atrial Fibrillation (AF)SomaScreenNCT07518446
Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)
A study testing Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen) in people with Atrial Fibrillation (AF) and Heart Failure, run by Amager Hospital at 1 site in Denmark.
Trial summary
People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation (AF), Heart Failure, Asthma (Diagnosis)
- What is being tested?
- Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,800 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2024to 30 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years or older.
- Referred to FACT or OPUS psychiatric outpatient clinics in the Capital Region of Denmark.
- Starting a new outpatient treatment episode in FACT or OPUS.
- Diagnosed with psychotic or affective disorders (ICD-10 F20-F39), including those with comorbid substance use disorders (F10-F19).
Who cannot join
- Individuals younger than 18 years.
- Patients in geriatric outpatient clinics.
- Individuals not in the target diagnosis group (i.e., without psychotic or affective disorders, F20-F39).
- Individuals who do not meet the inclusion criteria above.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Amager Hospital
Copenhagen, 2300
Lene F Eplov, MD, PhD, Associate Professor, +4520184687, Lene.Falgaard.Eplov@regionh.dk
About this study
Official title: Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) - Study Protocol for a Quasi-experimental Controlled Intervention Study With a Matched Cohort
People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of Denmark to improve the detection and follow-up of somatic disease among patients with psychotic and affective disorders.
This study evaluates whether integrating structured somatic screening into mental health services leads to improved identification and management of somatic disease compared with care as usual. Using a quasi-experimental controlled design with a matched cohort, outcomes among patients exposed to the SomaScreen intervention are compared with those of patients receiving usual care in comparable psychiatric outpatient clinics outside the Capital Region.
Read the detailed description
Background and Rationale
Individuals with severe mental illness experience pronounced health inequalities, including a markedly elevated risk of somatic disease and premature mortality. A substantial proportion of this excess mortality is attributable to common physical conditions such as cardiovascular disease, respiratory disease, diabetes, and cancer. These conditions are often underdiagnosed or insufficiently managed in this population due to complex interactions between illness-related factors, treatment side effects, socioeconomic vulnerability, and barriers in accessing somatic health care.
In Denmark, most diagnosis and treatment of somatic disease occurs in general practice, either directly or through referral to secondary care. However, patients with severe mental illness may face difficulties engaging with general practice, and coordination across sectors remains challenging. Strengthening somatic disease detection and care pathways within psychiatric services may therefore represent an important opportunity to reduce health inequalities.
The SomaScreen Intervention
Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) was implemented in psychiatric outpatient clinics in the Capital Region of Denmark as a service-level initiative to improve early detection and management of somatic disease. The intervention integrates structured somatic screening into psychiatric outpatient care and actively supports transitions to general practice.
Somatic examinations are conducted by specially trained somatic nurses and general practitioner consultants embedded within psychiatric outpatient clinics. A standardized consultation model is used, incorporating systematic preparation, extended consultation time, and a structured questioning approach tailored to patients with severe mental illness. When somatic disease is suspected or identified, referral to general practice is facilitated, including support with appointment booking and follow-up.
The intervention is delivered within Flexible Assertive Community Treatment (F-ACT) and OPUS outpatient clinics, both of which are multidisciplinary mental health service models for patients with severe mental illness. OPUS primarily serves young adults with early psychosis, whereas F-ACT serves a broader population with severe mental disorders across age groups. Both models emphasize continuity of care, assertive outreach, and treatment within patients' everyday environments.
Recruitment and Inclusion Criteria
Eligible participants are adult patients (18+) referred to F-ACT or OPUS outpatient clinics who are starting a new outpatient treatment episode. Patients must have a primary diagnosis of psychotic or affective disorder (F20-39) and may have comorbid substance use disorders (F10-19). Geriatric outpatient clinics are not included, and patients may be of any adult age. Patients who meet these criteria are systematically offered somatic screening.
Study Design
Because SomaScreen was implemented as a routine service initiative prior to the establishment of a research protocol, the intervention was not designed as a randomized clinical trial. Allocation to the intervention was determined by service delivery, and randomization was not feasible. Patients receiving SomaScreen therefore constitute a cohort defined by exposure to the intervention rather than an experimental arm.
To enable evaluation of intervention effects, the study uses a quasi-experimental controlled design with a matched cohort. Patients exposed to SomaScreen are compared with a control cohort receiving care as usual in comparable psychiatric outpatient clinics located in other major urban regions of Denmark. Matching is conducted to enhance comparability and reduce confounding.
Blinding is not applied in this study, as identification of intervention exposure is required for cohort construction and matching procedures. Participants in both the intervention and control cohorts are followed for up to two years from the start of the outpatient treatment episode, allowing longitudinal assessment of outcomes.
Intervention Cohort Operationalization
There is a single intervention cohort comprising all patients meeting inclusion criteria and starting a new outpatient treatment episode in SomaScreen-implementing FACT/OPUS clinics. Two complementary analysis approaches will be applied to this cohort:
Intention-to-treat analysis (primary): Includes all patients in the intervention cohort, regardless of actual participation in SomaScreen. This approach reflects real-world effectiveness under routine service conditions.
Adherence-stratified analysis (supplementary): Applied to patients captured in intervention-specific data collection (i.e., those who attended at least the initial somatic nurse screening). Patients will be stratified by adherence level to examine dose-response effects, with higher exposure values assigned to those completing additional intervention steps (screening completion, GP appointment booking, and GP consultation attendance).
Evaluation Framework
The evaluation comprises three complementary components: effectiveness, process, and health economic evaluation.
The effectiveness evaluation examines whether exposure to SomaScreen is associated with improved identification and management of somatic disease compared with care as usual. The process evaluation investigates whether the intended mechanisms of action occur in practice, for whom the intervention works best, and how the screening and referral components function within routine clinical settings. The health economic evaluation assesses whether the intervention represents a cost-effective use of health care resources.
Data Sources and Analysis Overview
The study combines intervention-specific data with nationwide Danish register data, linked at the individual level through secure, pseudonymized procedures. Register-based data enable longitudinal follow-up and comprehensive assessment of health care utilization and outcomes across sectors.
Analyses are conducted using appropriate regression-based methods for matched cohort data and clustered observations.
- Conditions
- Atrial Fibrillation (AF), Heart Failure, Asthma (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Diabetes, Cancer
- Being tested
- Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)
- Keywords
- Somatic screening, Early diagnosis, Continuity of patient care, Cohort studies, Mental disorders, Health status disparities
- Medical subject headings
- Atrial Fibrillation, Heart Failure, Asthma, Disease, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Neoplasms, Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)Diagnostic test
SomaScreen is a structured somatic health screening program for adults in psychiatric outpatient care (F-ACT and OPUS clinics). Trained somatic nurses and general practitioner consultants systematically assess patients for cardiovascular disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, and cancer, and may detect other somatic conditions. Patients with identified conditions are referred to their own general practitioner for follow-up and management. The intervention is distinguished from usual care by its systematic, multi-condition screening and structured referral process.
| Study group | Role | What they receive |
|---|---|---|
| SomaScreen Intervention Cohort | Experimental | Patients in this arm receive the SomaScreen intervention, consisting of systematic somatic screening conducted by trained somatic nurses and general practitioner consultants in psychiatric outpatient clinics (F-ACT and OPUS). The intervention focuses on detecting cardiovascular disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, and cancer, but may also identify other somatic conditions. Patients with detected conditions are referred to their general practitioner for follow-up or further management. This cohort is distinguished from the control arm by exposure to the structured somatic screening intervention. Receives: Diagnostic Test: Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen) |
| Matched Control Cohort (Care as Usual) | No intervention | Patients in this arm receive standard psychiatric outpatient care at clinics in urban areas outside the Capital Region. They do not receive the SomaScreen somatic screening intervention. Control clinics are matched to intervention clinics at the cluster level using propensity score matching based on clinic-level characteristics, including average age, sex distribution, distribution of socioeconomic status, distribution of psychiatric diagnoses, Charlson Comorbidity Index (CCI), number of patients attached to the clinic, number of employed physicians, and number of employed nurses. These patients continue their usual care, including routine monitoring and management of somatic conditions by their general practitioner or secondary care providers. This cohort is distinguished from the intervention arm by the absence of structured somatic screening. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Previously Undiagnosed Somatic Illness
Number of newly identified somatic (non-psychiatric) illnesses per patient in the intervention cohort compared with the matched control cohort. Analysis will use negative binomial regression to estimate relative risk of detection.
Measured: 2 years from start of intervention
Management of Somatic Conditions
Change in management of somatic conditions, comparing intervention and control cohorts. Data will be collected from national health registries.
Measured: 2 years from start of intervention
Secondary outcomes (3)
Intended Mechanisms
Quantitative assessment of whether the intended mechanisms of action of the intervention occur. Data collected from intervention records and linked registries.
Measured: 2 years from start of intervention
Screening and Referral Functioning
Qualitative assessment of how the process components operate in practice. Data collected via structured interviews, questionnaires, and process reports.
Measured: 2 years from start of intervention
Healthcare costs
Total healthcare costs in the intervention cohort compared with the matched control cohort. Costs include all registered healthcare services and prescription medicines. Data will be obtained from national health registries, including healthcare utilization and associated costs.
Measured: 2 years from start of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study start1 Sep 2024
- Primary completion30 Apr 2026 (estimated)
- Study completion30 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This study uses a parallel design in which patients receiving the SomaScreen intervention form one cohort, and a matched control cohort is constructed from patients in comparable urban psychiatric outpatient clinics outside the Capital Region. Allocation to the intervention cohort is determined by attendance at outpatient clinics where SomaScreen is implemented, while control cohort participants from similar urban settings are matched with intervention participants at the cluster level. Both cohorts are followed concurrently for up to two years.
- Masking
- None (open label)
- Enrolment
- 2,800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amager Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lene Falgaard Eplov, Amager Hospital
- Investigators
- Lene F Eplov, MD, PhD, Associate Professor, Principal investigator, Amager Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07518446
- Sponsor's protocol ID
- p-2024-15787
- Other IDs
- 2023-1305
- Acronym
- SomaScreen
- Status last verified
- Apr 2026
- First submitted
- 4 Feb 2026
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared, in accordance with Danish data protection regulations. Data contain sensitive health information from psychiatric patients and cannot be shared outside the research team.
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) - Study Protocol for a Quasi-experimental Controlled Intervention Study With a Matched Cohort
- ClinicalTrials.gov ID
- NCT07518446
- Acronym / sponsor ID
- SomaScreen / p-2024-15787
- Conditions
- Atrial Fibrillation (AF), Heart Failure, Asthma (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Diabetes, Cancer
- Keywords
- Somatic screening, Early diagnosis, Continuity of patient care, Cohort studies, Mental disorders, Health status disparities
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,800 participants (estimated)
- Lead sponsor
- Amager HospitalUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 30 Apr 2026 (estimated)
- Study completion
- 30 Oct 2028 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with severe mental illness have a substantially increased risk of undiagnosed and insufficiently treated somatic disease. Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) is a service-level intervention implemented in psychiatric outpatient clinics in the Capital Region of Denmark to improve the detection and follow-up of somatic disease among patients with psychotic and affective disorders.
This study evaluates whether integrating structured somatic screening into mental health services leads to improved identification and management of somatic disease compared with care as usual. Using a quasi-experimental controlled design with a matched cohort, outcomes among patients exposed to the SomaScreen intervention are compared with those of patients receiving usual care in comparable psychiatric outpatient clinics outside the Capital Region.
Detailed description
Background and Rationale
Individuals with severe mental illness experience pronounced health inequalities, including a markedly elevated risk of somatic disease and premature mortality. A substantial proportion of this excess mortality is attributable to common physical conditions such as cardiovascular disease, respiratory disease, diabetes, and cancer. These conditions are often underdiagnosed or insufficiently managed in this population due to complex interactions between illness-related factors, treatment side effects, socioeconomic vulnerability, and barriers in accessing somatic health care.
In Denmark, most diagnosis and treatment of somatic disease occurs in general practice, either directly or through referral to secondary care. However, patients with severe mental illness may face difficulties engaging with general practice, and coordination across sectors remains challenging. Strengthening somatic disease detection and care pathways within psychiatric services may therefore represent an important opportunity to reduce health inequalities.
The SomaScreen Intervention
Somatic Screening in the Capital Region Mental Health Service in Denmark (SomaScreen) was implemented in psychiatric outpatient clinics in the Capital Region of Denmark as a service-level initiative to improve early detection and management of somatic disease. The intervention integrates structured somatic screening into psychiatric outpatient care and actively supports transitions to general practice.
Somatic examinations are conducted by specially trained somatic nurses and general practitioner consultants embedded within psychiatric outpatient clinics. A standardized consultation model is used, incorporating systematic preparation, extended consultation time, and a structured questioning approach tailored to patients with severe mental illness. When somatic disease is suspected or identified, referral to general practice is facilitated, including support with appointment booking and follow-up.
The intervention is delivered within Flexible Assertive Community Treatment (F-ACT) and OPUS outpatient clinics, both of which are multidisciplinary mental health service models for patients with severe mental illness. OPUS primarily serves young adults with early psychosis, whereas F-ACT serves a broader population with severe mental disorders across age groups. Both models emphasize continuity of care, assertive outreach, and treatment within patients' everyday environments.
Recruitment and Inclusion Criteria
Eligible participants are adult patients (18+) referred to F-ACT or OPUS outpatient clinics who are starting a new outpatient treatment episode. Patients must have a primary diagnosis of psychotic or affective disorder (F20-39) and may have comorbid substance use disorders (F10-19). Geriatric outpatient clinics are not included, and patients may be of any adult age. Patients who meet these criteria are systematically offered somatic screening.
Study Design
Because SomaScreen was implemented as a routine service initiative prior to the establishment of a research protocol, the intervention was not designed as a randomized clinical trial. Allocation to the intervention was determined by service delivery, and randomization was not feasible. Patients receiving SomaScreen therefore constitute a cohort defined by exposure to the intervention rather than an experimental arm.
To enable evaluation of intervention effects, the study uses a quasi-experimental controlled design with a matched cohort. Patients exposed to SomaScreen are compared with a control cohort receiving care as usual in comparable psychiatric outpatient clinics located in other major urban regions of Denmark. Matching is conducted to enhance comparability and reduce confounding.
Blinding is not applied in this study, as identification of intervention exposure is required for cohort construction and matching procedures. Participants in both the intervention and control cohorts are followed for up to two years from the start of the outpatient treatment episode, allowing longitudinal assessment of outcomes.
Intervention Cohort Operationalization
There is a single intervention cohort comprising all patients meeting inclusion criteria and starting a new outpatient treatment episode in SomaScreen-implementing FACT/OPUS clinics. Two complementary analysis approaches will be applied to this cohort:
Intention-to-treat analysis (primary): Includes all patients in the intervention cohort, regardless of actual participation in SomaScreen. This approach reflects real-world effectiveness under routine service conditions.
Adherence-stratified analysis (supplementary): Applied to patients captured in intervention-specific data collection (i.e., those who attended at least the initial somatic nurse screening). Patients will be stratified by adherence level to examine dose-response effects, with higher exposure values assigned to those completing additional intervention steps (screening completion, GP appointment booking, and GP consultation attendance).
Evaluation Framework
The evaluation comprises three complementary components: effectiveness, process, and health economic evaluation.
The effectiveness evaluation examines whether exposure to SomaScreen is associated with improved identification and management of somatic disease compared with care as usual. The process evaluation investigates whether the intended mechanisms of action occur in practice, for whom the intervention works best, and how the screening and referral components function within routine clinical settings. The health economic evaluation assesses whether the intervention represents a cost-effective use of health care resources.
Data Sources and Analysis Overview
The study combines intervention-specific data with nationwide Danish register data, linked at the individual level through secure, pseudonymized procedures. Register-based data enable longitudinal follow-up and comprehensive assessment of health care utilization and outcomes across sectors.
Analyses are conducted using appropriate regression-based methods for matched cohort data and clustered observations.
Study design
- Primary purpose
- Screening
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study uses a parallel design in which patients receiving the SomaScreen intervention form one cohort, and a matched control cohort is constructed from patients in comparable urban psychiatric outpatient clinics outside the Capital Region. Allocation to the intervention cohort is determined by attendance at outpatient clinics where SomaScreen is implemented, while control cohort participants from similar urban settings are matched with intervention participants at the cluster level. Both cohorts are followed concurrently for up to two years.
| Arm | Type | Receives |
|---|---|---|
| SomaScreen Intervention Cohort | Experimental | Diagnostic Test: Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)Patients in this arm receive the SomaScreen intervention, consisting of systematic somatic screening conducted by trained somatic nurses and general practitioner consultants in psychiatric outpatient clinics (F-ACT and OPUS). The intervention focuses on detecting cardiovascular disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, and cancer, but may also identify other somatic conditions. Patients with detected conditions are referred to their general practitioner for follow-up or further management. This cohort is distinguished from the control arm by exposure to the structured somatic screening intervention. |
| Matched Control Cohort (Care as Usual) | No intervention | –Patients in this arm receive standard psychiatric outpatient care at clinics in urban areas outside the Capital Region. They do not receive the SomaScreen somatic screening intervention. Control clinics are matched to intervention clinics at the cluster level using propensity score matching based on clinic-level characteristics, including average age, sex distribution, distribution of socioeconomic status, distribution of psychiatric diagnoses, Charlson Comorbidity Index (CCI), number of patients attached to the clinic, number of employed physicians, and number of employed nurses. These patients continue their usual care, including routine monitoring and management of somatic conditions by their general practitioner or secondary care providers. This cohort is distinguished from the intervention arm by the absence of structured somatic screening. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients aged 18 years or older.
- Referred to FACT or OPUS psychiatric outpatient clinics in the Capital Region of Denmark.
- Starting a new outpatient treatment episode in FACT or OPUS.
- Diagnosed with psychotic or affective disorders (ICD-10 F20-F39), including those with comorbid substance use disorders (F10-F19).
Key exclusion criteria (4 listed)
- Individuals younger than 18 years.
- Patients in geriatric outpatient clinics.
- Individuals not in the target diagnosis group (i.e., without psychotic or affective disorders, F20-F39).
- Individuals who do not meet the inclusion criteria above.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)SomaScreen is a structured somatic health screening program for adults in psychiatric outpatient care (F-ACT and OPUS clinics). Trained somatic nurses and general practitioner consultants systematically assess patients for cardiovascular disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, and cancer, and may detect other somatic conditions. Patients with identified conditions are referred to their own general practitioner for follow-up and management. The intervention is distinguished from usual care by its systematic, multi-condition screening and structured referral process. | Diagnostic test | SomaScreen Intervention Cohort |
Primary outcome
Previously Undiagnosed Somatic Illness
Time frame: 2 years from start of intervention
Number of newly identified somatic (non-psychiatric) illnesses per patient in the intervention cohort compared with the matched control cohort. Analysis will use negative binomial regression to estimate relative risk of detection.
Management of Somatic Conditions
Time frame: 2 years from start of intervention
Change in management of somatic conditions, comparing intervention and control cohorts. Data will be collected from national health registries.
3 secondary outcomes
Intended Mechanisms
Time frame: 2 years from start of intervention
Screening and Referral Functioning
Time frame: 2 years from start of intervention
Healthcare costs
Time frame: 2 years from start of intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared, in accordance with Danish data protection regulations. Data contain sensitive health information from psychiatric patients and cannot be shared outside the research team.
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lene F Eplov, MD, PhD, Associate Professor principal investigator
Amager Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen) in people with Atrial Fibrillation (AF) and Heart Failure, run by Amager Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lene F Eplov, MD, PhD, Associate Professor (+4520184687, Lene.Falgaard.Eplov@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Previously Undiagnosed Somatic Illness (time frame: 2 years from start of intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.